Musa balbisiana and Musa paradisiaca Starches Increase SCFA and Caspase-3 as well as Decrease β-glucuronidase and MDA of Mouse Model for Colon Cancer
Abstract
BACKGROUND: Administration of resistant starch (RS) influences the diversity and the composition of microbiota as well as inhibits the growth of cancer cell. Banana as a potential source of RS has been reported. Although Musa paradisiaca has been reported to induce apoptosis in colon cancer cells, Musa balbisiana, which has low glycemic index and suitable for particular patients, has not been investigated yet.
METHODS: Starches of M. balbisiana and M. paradisiaca were prepared and mixed with other components to make 3 types of mouse pellets. Mouse model for colon cancer was prepared and fed with different types of mouse pellets. Blood was collected and processed for measuring β-glucuronidase and malondialdehyde (MDA) with Enzyme-linked Immunosorbent Assay (ELISA) method. Resected ceca were incised to collect the inner part for short-chain fatty acid (SCFA) measurement with gas chromatography analysis. Resected colas were fixed and processed for immunohistochemistry to detect Caspase-3.
RESULTS: Colon-cancer-mice fed with the M. balbisiana and M. paradisiaca starches-contained pellets had significant higher concentrations of total SCFA (p=0.003), acetic acid (p=0.000), propionic acid (p=0.000) and butyric acid (p=0.000); lower concentration of β-glucuronidase (p<0.001); higher Caspase-3 score (p=0.040); and lower MDA concentration (p<0.001) than colon-cancer-mice fed with standard pellet (control).
CONCLUSION: M. balbisiana and M. paradisiaca starches could be suggested as potential anti-colon cancer RS. Further research should be carried out to disclose the starches mechanisms in colon cancer cell.
KEYWORDS: Musa balbisiana, Musa paradisiaca, colon cancer, resistant starch, Caspase-3, SCFA, β-glucuronidase, malondialdehyde
Full Text:
PDFReferences
Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, et al. Epidemiology of meningiomas. Neurochirurgie. 2018; 64: 5-14, CrossRef.
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018; 20 (Suppl 4): iv1-iv86, CrossRef.
Watts J, Box G, Galvin A, Brotchie P, Trost N, Sutherland T. Magnetic resonance imaging of meningiomas: a pictorial review. Insights Imaging. 2014; 5: 113-22, CrossRef.
Villanueva-Meyer JE, Mabray MC, Cha S. Current clinical brain tumor imaging. Neurosurgery. 2017; 81: 397-415, CrossRef.
Tamrazi B, Shiroishi MS, Liu CSJ. Advanced imaging of intracranial meningiomas. Neurosurg Clin N Am. 2016; 27: 137-43, CrossRef.
Staedtke V, Dzaye OD, Holdhoff M. Actionable molecular biomarkers in primary brain tumors. Trends Cancer. 2016; 2: 338-49, CrossRef.
Ueda S, Mineta T, Nakahara Y, Okamoto H, Shiraishi T, Tabuchi K. Induction of the DNA repair gene O6-methylguanine—DNA methyltransferase by dexamethasone in glioblastomas. J Neurosurg. 2004; 101: 659-63, CrossRef.
Panagopoulos I, Gorunova L, Leske H, Niehussman P, Johannessen LE, Staurseth J, et al. Pyrosequencing analysis of MGMT promoter methylation in meningioma. Cancer Genom Proteom. 2018; 15: 379-85, CrossRef.
Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, et al. O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One. 2011; 6: e17156, CrossRef.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131: 803-20, CrossRef.
Tambaip T, Br Karo M, Hatta M, Dwiyanti R, Natzir R, Nasrum Mas M, et al. Immunomodulatory effect of orally red fruit (Pandanus conoideus) extract on the expression of CC chemokine receptor 5 mRNA in HIV patients with antiretroviral therapy. Res J Immunol. 2018; 11: 15-21, CrossRef.
Sirait RH, Hatta M, Ramli M, Islam AA. Systemic lidocaine inhibits high‑mobility group box 1 messenger ribonucleic acid expression and protein in BALB/c mice after closed fracture musculoskeletal injury. Saudi J Anesth. 2018; 12: 395-8, CrossRef.
Jabini R, Moradi A, Afsharnezhad S, Ayatollahi H, Behravan J, Raziee HR, et al. Pathodiagnostic parameters and evaluation of O 6 - methyl guanine methyl transferase gene promoter methylation in meningiomas. Gene. 2014; 538: 348-53, CrossRef.
Larijani L, Madjd Z, Samadikuchaksaraei A, Younespour S, Zham H, Rakhshan A, et al. Methylation of O 6-methyl guanine methyltransferase gene promoter in meningiomas - comparison between tumor grades I, II, and III. Asian Pacific J Cancer Prev. 2014; 15: 33-8, CrossRef.
Van Alkemade H, De Leau M, Dieleman EMT, Kardaun JWPF, Van Os R, Vandertop WP, et al. Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol. 2012; 14: 658-66, CrossRef.
Surov A, Ginat DT, Sanverdi E, Lim CCT, Hakyemez B, Yogi A, et al. Use of diffusion weighted imaging in differentiating between malignant and benign meningiomas: a multicenter analysis. World Neurosurg. 2016; 88: 598-602, CrossRef.
Watanabe Y, Yamasaki F, Kajiwara Y, Takayasu T, Nosaka R, Akiyama Y, et al. Preoperative histological grading of meningiomas using apparent diffusion coefficient at 3T MRI. Eur J Radiol. 2013; 82: 658-63, CrossRef.
Toh CH, Castillo M, Wong AMC, Wei KC, Wong HF, Ng SH, et al. Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. Am J Neuroradiol. 2008; 29: 1630-5, CrossRef.
Abdel-Kerim A, Shehata M, El Sabaa B, Fadel S, Heikal A, Mazloum Y. Differentiation between benign and atypical cranial Meningiomas. Can ADC measurement help? MRI findings with histopathological correlation. Egypt J Radiol Nucl Med. 2018; 49: 172-5, CrossRef.
Lu Y, Liu L, Luan S, Xiong J, Geng D, Yin B. The diagnostic value of texture analysis in predicting WHO grades of meningiomas based on ADC maps: an attempt using decision tree and decision forest. Eur Radiol. 2019; 29: 1318-28, CrossRef.
Santelli L, Ramondo G, Della Puppa A, Ermani M, Scienza R, D’Avella D, et al. Diffusion-weighted imaging does not predict histological grading in meningiomas. Acta Neurochir (Wien). 2010; 152: 1315-9, CrossRef.
Sanverdi SE, Ozgen B, Oguz KK, Mut M, Dolgun A, Soylemezoglu F, et al. Is diffusion-weighted imaging useful in grading and differentiating histopathological subtypes of meningiomas? Eur J Radiol. 2012; 81: 2389-95, CrossRef.
Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong DM. Peritumoral brain regions in gliomas and meningiomas: Investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology. 2004; 232: 451-60, CrossRef.
Hwang WL, Marciscano AE, Niemierko A, Kim DW, Stemmer-Rachamimov AO, Curry WT, et al. Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro Oncol. 2016; 18: 863-72, CrossRef.
Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, et al. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018; 139: 469-78, CrossRef.
Chang IW, Lin JW, Wu YT. The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution. J Neurooncol. 2011; 105: 563-72, CrossRef.
Bello MJ, Amiñoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, et al. DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol. 2004; 108: 413-21, CrossRef.
Aydemir F, Yurtcu E, Balci TB, Sahin FI, Gulsen S, Altinors N. Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients. Genet Test Mol Biomarkers. 2012; 16: 335-40, CrossRef.
Drabycz S, Roldán G, de Robles P, Adler D, McIntyre JB, Magliocco AM, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010; 49: 1398-405, CrossRef.
Moon WJ, Choi JW, Roh HG, Lim SD, Koh YC. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology. 2012; 54: 555-63, CrossRef.
Romano A, Calabria LF, Tavanti F, Minniti G, Rossi-Espagnet MC, Coppola V, et al. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol. 2013; 23: 513-20, CrossRef.
Gupta A, Omuro AMP, Shah AD, Graber JJ, Shi W, Zhang Z, et al. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology. 2012; 54: 641-3, CrossRef.
DOI: https://doi.org/10.18585/inabj.v13i1.1320
Copyright (c) 2021 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
